<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04005586</url>
  </required_header>
  <id_info>
    <org_study_id>CSP-034</org_study_id>
    <nct_id>NCT04005586</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate The Safety and Effectiveness of Performing 0.50 Diopter Astigmatism Correction on the Commercially Available RxSight Light Adjustable Lens (LAL)</brief_title>
  <official_title>A Prospective Controlled Multi-Center Clinical Study to Evaluate The Safety and Effectiveness of Performing 0.50 Diopter Astigmatism Correction on the Commercially Available RxSight Light Adjustable Lens (LAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RxSight, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RxSight, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and effectiveness of performing&#xD;
      0.50 D cylinder correction on the RxSight Light Adjustable Lens (LAL) in patients who have&#xD;
      undergone implantation with the FDA approved, commercially available LAL.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Actual">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All subjects will receive the same treatment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Manifest Refraction Cylinder (MRCYL) Compared Between the Three Study Groups, LAL Treatment Group and Historical Control Groups</measure>
    <time_frame>Post Op Month 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Manifest Refraction Cylinder (MRCYL) Compared Between the Three Study Groups, LAL Treatment Group and Historical Control Groups</measure>
    <time_frame>Post Op Month 3</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Safety: ISO 11979-7 Number of Eyes With Ocular Adverse Events (Device Related and Unrelated)</measure>
    <time_frame>Through study completion, an average of 3 months</time_frame>
    <description>Number of study eyes experiencing Ocular adverse events (device related and unrelated)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Aphakia</condition>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Light Delivery Device (LDD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient's study eye will undergo light delivery treatments to the commercially available light adjustable lens.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Light Delivery Device (LDD)</intervention_name>
    <description>Study eye will undergo Light delivery Device treatments</description>
    <arm_group_label>Light Delivery Device (LDD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A study eye implanted with the commercially approved LAL that has not undergone any&#xD;
             previous LDD treatments&#xD;
&#xD;
          -  A study eye with manifest refraction cylinder of 0.50 D measured by two independent&#xD;
             examiners at the Adjustment #1 visit prior to the first light adjustment treatment.&#xD;
&#xD;
          -  Sign a written Informed Consent form and be willing to receive light treatment for&#xD;
             their 0.50 D of cylinder.&#xD;
&#xD;
          -  Between the ages of 40 and 80 inclusive on the day the informed consent form is&#xD;
             signed.&#xD;
&#xD;
          -  Good vision in the fellow eye with best corrected distance visual acuity (BCDVA) 20/40&#xD;
             or better.&#xD;
&#xD;
          -  Willing and able to comply with the requirements for study specific procedures and&#xD;
             visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-existing macular disease in the study eye.&#xD;
&#xD;
          -  History of uveitis in the study eye.&#xD;
&#xD;
          -  Has undergone previous corneal or intraocular surgery in the study eye, except for the&#xD;
             cataract surgery and eyes with previous pterygium excision are permitted as long as&#xD;
             the pterygium did not extend more than 2mm onto the cornea from the limbus.&#xD;
&#xD;
          -  Subjects taking systemic medication that may increase sensitivity to UV light.&#xD;
&#xD;
          -  Subjects taking a systemic medication that is considered toxic to the retina such as&#xD;
             tamoxifen.&#xD;
&#xD;
          -  History of ocular herpes simplex virus in the study eye.&#xD;
&#xD;
          -  Subject who has participated within another ophthalmic clinical trial within the last&#xD;
             3 months.&#xD;
&#xD;
          -  Sutures used at the time of surgery to close the incision wound in the study eye&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cleveland Eye Clinic</name>
      <address>
        <city>Brecksville</city>
        <state>Ohio</state>
        <zip>44141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vance Thompson Vision Clinic</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 26, 2019</study_first_submitted>
  <study_first_submitted_qc>June 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <results_first_submitted>March 18, 2021</results_first_submitted>
  <results_first_submitted_qc>May 14, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 11, 2021</results_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Light Delivery Device</keyword>
  <keyword>LDD</keyword>
  <keyword>Intraocular lens</keyword>
  <keyword>Light Adjustable Lens</keyword>
  <keyword>LAL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Astigmatism</mesh_term>
    <mesh_term>Aphakia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 23, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT04005586/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Light Delivery Device (LDD)</title>
          <description>Patient's study eye will undergo light delivery treatments to the commercially available light adjustable lens.&#xD;
Light Delivery Device (LDD): Study eye will undergo Light Delivery Device treatments</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Light Delivery Device (LDD)</title>
          <description>Patient's study eye will undergo light delivery treatments to the commercially available light adjustable lens.&#xD;
Light Delivery Device (LDD): Study eye will undergo Light Delivery Device treatments</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.2" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Data not collected</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Manifest Refraction Cylinder (MRCYL) Compared Between the Three Study Groups, LAL Treatment Group and Historical Control Groups</title>
        <time_frame>Post Op Month 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Light Delivery Device (LDD)</title>
            <description>Patient's study eye will undergo light delivery treatments to the commercially available light adjustable lens.&#xD;
Light Delivery Device (LDD): Study eye will undergo Light Delivery Device treatments</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Manifest Refraction Cylinder (MRCYL) Compared Between the Three Study Groups, LAL Treatment Group and Historical Control Groups</title>
          <units>Diopter (D)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Two different historical controls implanted under NCT01496066 were used.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The comparison was made by descriptive statistics.</non_inferiority_desc>
            <other_analysis_desc>The LAL treatment group had a mean MRCYL of -0.14 (+/- 0.21D) compared to -0.33 (+/- 0.29D) and -0.40 (+/- 0.36D) for the LAL historical control group and the monofocal IOL historical control group in NCT01496066 respectively.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Manifest Refraction Cylinder (MRCYL) Compared Between the Three Study Groups, LAL Treatment Group and Historical Control Groups</title>
        <time_frame>Post Op Month 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Light Delivery Device (LDD)</title>
            <description>Patient's study eye will undergo light delivery treatments to the commercially available light adjustable lens.&#xD;
Light Delivery Device (LDD): Study eye will undergo Light Delivery Device treatments</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Manifest Refraction Cylinder (MRCYL) Compared Between the Three Study Groups, LAL Treatment Group and Historical Control Groups</title>
          <units>Diopter (D)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Two different historical controls implanted under NCT01496066 were used.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The comparison was made by descriptive statistics.</non_inferiority_desc>
            <other_analysis_desc>The LAL treatment group MRCYL change from baseline was 0.36 (+/- 0.21D) compared to 0.17 (+/- 0.29D) and 0.10 (+/- 0.36D) for the LAL historical control group and the monofocal IOL historical control group in NCT01496066, respectively.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Safety: ISO 11979-7 Number of Eyes With Ocular Adverse Events (Device Related and Unrelated)</title>
        <description>Number of study eyes experiencing Ocular adverse events (device related and unrelated)</description>
        <time_frame>Through study completion, an average of 3 months</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Light Delivery Device (LDD)</title>
            <description>Patient's study eye will undergo light delivery treatments to the commercially available light adjustable lens.&#xD;
Light Delivery Device (LDD): Study eye will undergo Light Delivery Device treatments</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: ISO 11979-7 Number of Eyes With Ocular Adverse Events (Device Related and Unrelated)</title>
          <description>Number of study eyes experiencing Ocular adverse events (device related and unrelated)</description>
          <population>Safety population</population>
          <units>eyes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study completion, an average of 3 months.</time_frame>
      <desc>Non-ocular adverse events were not collected. Adverse events were counted by eye.</desc>
      <group_list>
        <group group_id="E1">
          <title>Light Delivery Device (LDD)</title>
          <description>Patient's study eye will undergo light delivery treatments to the commercially available light adjustable lens.&#xD;
Light Delivery Device (LDD): Study eye will undergo Light Delivery Device treatments</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Non-clinically significant cystoid macular edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Non-clinically significant cystoid macular edema in non-study eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Posterior Capsular Opacity (PCO) that requires YAG Capsulotomy treatment</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeffrey Ha, Senior Director of Clinical Research</name_or_title>
      <organization>RxSight</organization>
      <phone>949-521-7870</phone>
      <email>jha@rxsight.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

